Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.56 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6263041 | 0.97 | SIGMAR1 (0.54) | SIGMAR1CYP2D6DRD2ALDH1A1CYP3A4 | |
| SCHEMBL2342552 | 0.90 | SIGMAR1 (0.55) | SIGMAR1CYP2D6ALDH1A1CYP3A4TSHR | |
| SCHEMBL18785016 | 0.84 | SIGMAR1 (0.54) | SIGMAR1CYP2D6DRD2ALDH1A1CYP3A4 | |
| SCHEMBL21254493 | 0.83 | MGLL (0.58) | SIGMAR1CYP2D6CYP3A4TSHR | |
| SCHEMBL18785020 | 0.80 | MGLL (0.56) | SIGMAR1CYP2D6CYP3A4 | |
| SCHEMBL18785015 | 0.80 | SIGMAR1 (0.51) | SIGMAR1CYP2D6DRD2ALDH1A1CYP3A4 | |
| SCHEMBL18766512 | 0.80 | SIGMAR1 (0.50) | SIGMAR1CYP2D6DRD2ALDH1A1CYP3A4 | |
| SCHEMBL1966477 | 0.80 | SIGMAR1 (0.61) | SIGMAR1CYP2D6DRD2ALDH1A1CYP3A4 | |
| SCHEMBL8914175 | 0.79 | SIGMAR1 (0.60) | SIGMAR1CYP2D6DRD2CYP3A4TSHR | |
| SCHEMBL18785257 | 0.79 | SIGMAR1 (0.49) | SIGMAR1CYP2D6DRD2ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS | 2022-12-29 | — | — | US | disclosed |
| WO-2021081272-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | ARKUDA THERAPEUTICS (US) | 2021-04-29 | — | — | WO | disclosed |
| EP-1568688-B1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARM CO LTD (JP) | 2011-08-31 | — | — | EP | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-7816375-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | AQUILA BRIAN M | 2009-10-15 | — | — | US | disclosed |
| US-7517892-B2 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. (US) | 2009-04-14 | — | — | US | disclosed |
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SEPRACOR INC. | 2003-03-13 | — | — | US | disclosed |
| WO-2002069895-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHODS OF USE THEREOF | SEPRACOR, INC. (US) | 2002-09-12 | — | — | WO | disclosed |
| WO-2002022572-A2 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF (NEUROTRANSMISSION) | SEPRACOR, INC. (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1187810-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2002-03-20 | — | — | EP | disclosed |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | SEPRACOR INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001092226-A1 | HETEROCYCLIC ANALGESIC COMPOUNDS AND METHOD OF USE THEREOF | SEPRACOR, INC. (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2000071518-A2 | HETEROCYCLIC ANALGESIC COMPOUNDS AND THEIR USE | SEPRACOR, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0152236-B1 | ARYLOXYMETHYLPYRROLIDINOLS AND PIPERIDINOLS HAVING ANTIDEPRESSANT, ANTIARHYTHMIC OR HYPOTENSIVE ACTIVITY | A.H. ROBINS COMPANY, INCORPORATED (US) | 1990-04-18 | — | — | EP | disclosed |
| EP-0152236-A2 | Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarhythmic or hypotensive activity | A.H. ROBINS COMPANY, INCORPORATED (US) | 1985-08-21 | — | — | EP | disclosed |
| US-4508724-A | Aryloxymethylpyrrolidinols and piperidinols having antidepressant, antiarrhythmic or hypotensive activity | A. H. ROBINS COMPANY, INC. (US) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050309-A1 | Ligands for monoamine receptors and transporters, and methods of use thereof | SLC6A2, OPRL1, SLC18A2 | SIGMAR1 77/4885CYP2D6 549/4885DRD2 134/4885 |
| US-20220409593-A1 | PROGRANULIN MODULATORS AND METHODS OF USING THE SAME | GRN, PSEN1, PSEN2 | SIGMAR1 3357/4885CYP2D6 4593/4885DRD2 4454/4885 |
| US-20020016337-A1 | Heterocyclic analgesic compounds and methods of use thereof | OPRL1, TRPV1, OPRK1 | SIGMAR1 40/4885CYP2D6 462/4885DRD2 450/4885 |
| US-20090258901-A1 | LIGANDS FOR MONOAMINE RECEPTORS AND TRANSPORTERS, AND METHODS OF USE THEREOF | SLC6A2, OPRL1, SLC18A2 | SIGMAR1 77/4885CYP2D6 549/4885DRD2 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.